Daiichi Sankyo: Quizartinib Marketing Authorization Application Validated by EMA for Treatment of Adult Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia

Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone Daiichi Sankyo (TSE: 4568) today announced

Related Keywords

United States ,Japan ,Texas ,America ,American ,Zuccae Ann ,Masashi Kawase ,Simone Jendsch Dowe ,Ken Takeshita ,Daiichi Sankyo ,Daiichi Sankyo Europe Gmb ,Jennifer Brennan ,Daiichi Sankyo Inc ,University Of Texas Md Anderson Cancer Center ,Drug Administration ,European Hematology Association ,Sustainable Development Of Society ,Daiichi Sankyo Co Ltd ,Innovative Global Healthcare Company ,European Medicines Agency ,Committee For Medicinal Products Human Use ,American Cancer Society ,Global Head ,Medicinal Products ,Human Use ,North America ,Acute Myeloid Leukemia ,Cancer Center ,Orphan Drug Designation ,Fast Track Designation ,Global Healthcare Company Contributing ,Sustainable Development ,Cancer Society ,Key Statistics ,Acute Myeloid ,Updated January ,Population Fact Sheet ,Updated March ,Sankyo Europe Gmbh ,Daiichi ,Sankyo ,Quizartinib ,Marketing ,Authorization ,Application ,Validated ,Treatment ,Adult ,Patients ,Ewly ,Diagnosed ,Flt3 ,Positive ,Cute ,Amyeloid ,Leukemia ,